中国专家共识(英文):口服药物治疗成熟性B细胞淋巴瘤(2020年版)

2022-09-24 Front Med .

中国专家共识:口服药物治疗成熟性B细胞淋巴瘤(2020年版)

中文标题:

中国专家共识(英文):口服药物治疗成熟性B细胞淋巴瘤(2020年版)

英文标题:

Chinese expert consensus on oral drugs for the treatment of mature B-cell lymphomas (2020 edition)

发布机构:

发布日期:

2022-09-24

简要介绍:

中国专家共识:口服药物治疗成熟性B细胞淋巴瘤(2020年版)

相关资料下载:
[AttachmentFileName(sort=1, fileName=20220925043639-b8eaf2de-7562(科研通-ablesci.com).pdf)] GetToolGuiderByIdResponse(projectId=1, id=20f521c002692eb8, title=中国专家共识(英文):口服药物治疗成熟性B细胞淋巴瘤(2020年版), enTitle=Chinese expert consensus on oral drugs for the treatment of mature B-cell lymphomas (2020 edition), guiderFrom=Front Med ., authorId=0, author=, summary=中国专家共识:口服药物治疗成熟性B细胞淋巴瘤(2020年版), cover=https://img.medsci.cn/Random/health-insurance-PK235DP.jpg, journalId=0, articlesId=null, associationId=0, associationName=, associationIntro=, copyright=0, guiderPublishedTime=Sat Sep 24 00:00:00 CST 2022, originalUrl=, linkOutUrl=, content=<p>中国专家共识:口服药物治疗成熟性B细胞淋巴瘤(2020年版)</p>, tagList=[TagDto(tagId=462208, tagName=成熟B细胞淋巴瘤)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤, tenant=100), CategoryDto(categoryId=21, categoryName=血液科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=71290, articleKeyword=成熟B细胞恶性肿瘤, articleKeywordNum=6, guiderKeywordId=94646, guiderKeyword=儿童成熟B细胞淋巴瘤, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=1, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=8975, appHits=76, showAppHits=0, pcHits=261, showPcHits=8899, likes=1, shares=9, comments=1, approvalStatus=1, publishedTime=Fri Sep 30 10:32:00 CST 2022, publishedTimeString=2022-09-24, pcVisible=1, appVisible=1, editorId=0, editor=lixiang, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=12, createdBy=null, createdName=lixiang, createdTime=Sun Sep 25 09:37:10 CST 2022, updatedBy=6459136, updatedName=艺玮, updatedTime=Tue Jan 02 12:26:30 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=20220925043639-b8eaf2de-7562(科研通-ablesci.com).pdf)])
20220925043639-b8eaf2de-7562(科研通-ablesci.com).pdf
下载请点击:
评论区 (1)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2091201, encodeId=8442209120159, content=1, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6ac08355190, createdName=ms6000001300804578, createdTime=Fri Sep 30 14:57:43 CST 2022, time=2022-09-30, status=1, ipAttribution=)]
    2022-09-30 ms6000001300804578

    1

    0

拓展阅读

CLIN CANCER RES:靶向PI3Kδ治疗成熟B细胞恶性肿瘤

B细胞受体(BCR)异常活动与成熟B细胞肿瘤发病密切相关,这一概念已被BCR相关酶BTK和PI3Kδ抑制剂的临床成功部分验证。这些抑制剂也存在缺陷,包括完全反应不足,获得性耐药和毒性。CLIN CANCER RES近期发表了一篇文章,研究cyclic-AMP/PDE4信号通路抑制PI3K机制,寻找在该机制基础上的联合策略治疗成熟B细胞恶性肿瘤。

儿童成熟B细胞淋巴瘤诊疗规范(2019年版)

中华人民共和国国家卫生健康委员会 · 2019-09-05